Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,051 recruiting studies in this area right now.
By phase
- Not applicable2,997
- Phase 21,057
- Phase 1792
- Phase 1/Phase 2437
- Phase 3436
- Phase 4234
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma327
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis132
- Type 1 Diabetes130
- Atopic Dermatitis125
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia95
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Diabetes Mellitus, Type 163
- Hodgkin Lymphoma63
- Leukemia63
- Mantle Cell Lymphoma62
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic49
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California496
- Maryland200
- Alabama178
- Florida149
- Arizona147
- Massachusetts116
- New York116
- Texas112
- Illinois83
- Colorado82
Recruiting studies6,051 total
- NCT07690345Recruiting
Fungal status and outlook in allergic bronchopulmonary aspergillosis
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
Jinan, ShandongAges 18 years+ - NCT05806580RecruitingPhase 4
Second relma-cel infusion for returning B-cell lymphoma
This trial looks at giving a second dose of relma-cel (a type of CAR-T therapy) for B-cell lymphoma that came back or did not fully respond after the first treatment. It may help shrink tumors again, but it requires that side effects from the first treatment and pre-chemo are mostly gone and that you meet infection and blood-test safety checks.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05348213RecruitingPhase 2
Targeted drugs plus R-ICE chemo for relapsed lymphoma
This Phase 2 trial studies targeted drugs combined with R-ICE chemotherapy in people with diffuse large B-cell lymphoma (DLBCL) that has come back or hasn’t responded. It may help shrink the lymphoma after prior treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06479603RecruitingPhase 4
Nintedanib for lung scarring from sarcoidosis
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
ChandigarhAges Any age - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT03684655RecruitingPhase 2
PET-MR scan study of immune activity in people with HIV
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
San Francisco, CaliforniaAges 18 years+ - NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+ - NCT04607174Recruiting
Test knee muscle activation in people with nerve or movement disorders
This study checks how well your knee muscles “turn on” during guided, controlled knee movements. It may help researchers understand movement problems and improve testing or therapies for neuromotor (nerve/movement) disorders.
Milan, MIAges 18–70 - NCT06659653RecruitingEarly Phase 1
PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Jinzhou, HubeiAges 18–70 - NCT06659276Recruiting
Comparing two imaging methods for multiple myeloma
This trial compares two whole-body imaging scans (full-body MRI using DWI and a PET/CT scan) to see which does a better job detecting and staging active multiple myeloma. If you have been newly diagnosed or are being evaluated for suspected symptomatic myeloma, joining could help doctors learn which test is best for planning your care.
BolognaAges 18 years+ - NCT07684131Recruiting
Observational study of Philadelphia-positive ALL treatments
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
AmiensAges 18 years+ - NCT07685340Recruiting
Cupping vs Massage Tool for Chronic Low Back Pain
This trial tests two hands-on therapies—dry cupping and a special massage technique—to see which works better for long-term low back pain caused by muscle knots. You may be able to join if your pain has lasted over 3 months and you have trigger points.
Rawalpindi, Punjab ProvinceAges 25–45 - NCT07685717RecruitingPhase 2
Pirtobrutinib for older adults with CLL
This trial tests a new pill, pirtobrutinib, for people 75 or older with chronic lymphocytic leukemia (CLL) who have never had treatment before. The goal is to see if it helps control the disease with manageable side effects.
Columbus, OhioAges 75 years+ - NCT07681388Recruiting
CAR-T cell therapy for hard-to-treat pemphigus
This study tests a new type of immune therapy called CAR-T cells, made from your own blood cells, to treat severe pemphigus vulgaris that hasn't responded to standard treatments like steroids and rituximab. The goal is to see if this treatment can control the disease and reduce the need for ongoing medications.
Wuhan, HubeiAges 18–70 - NCT07686484RecruitingEarly Phase 1
Testing a new drug in healthy volunteers
This trial tests an experimental drug called HRS-3095 in healthy people to check its safety and how the body handles it. It may help find the right dose for future studies.
Bayswater, VictoriaAges 18–55 - NCT07683325RecruitingPhase 2
Study of ontunisertib for fibrostenosing Crohn's disease
This trial tests an investigational drug called ontunisertib versus a placebo in people with Crohn's disease that has caused narrowing (strictures) in the small intestine. It aims to see if the drug can help without needing surgery or other procedures.
Bradenton, FloridaAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Duarte, CaliforniaAges 18 years+ - NCT07682896RecruitingPhase 2
Testing YB-101 for safety and effectiveness in Graves' disease
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Gilbert, ArizonaAges 18 years+ - NCT07684157RecruitingPhase 2
Testing a new drug for active rheumatoid arthritis
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
San Francisco, CaliforniaAges 18 years+ - NCT06176027RecruitingPhase 1/Phase 2
New drug combo for returning AITL lymphoma
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06663111Recruiting
Rituximab and Ocrelizumab levels in Multiple Sclerosis
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Bergen, VestlandAges 18–60 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT07678268RecruitingPhase 4
Comparing HIV treatments for virologically suppressed men
This trial tests if a two-drug HIV regimen (darunavir/cobicistat plus lamivudine) works as well as a three-drug regimen (darunavir/cobicistat plus tenofovir alafenamide/emtricitabine) in men whose HIV is already suppressed. The goal is to find a simpler, effective option that may have fewer side effects.
Mexico City, Mexico CityAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,051 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,083 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.